Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Study ID: NCT03801876
Start Date: 2019-03-15
End Date: 2031-12-21
Study Type

Interventional

Study Phase

Phase3

No. of Participants

300

Intervention / Treatment

Carboplatin

Esophandomy

Intensity-Modulated Radiation Therapy

Paclitaxel

Proton Beam Radiation Therapy

Quality-of-Life Assessment

Administration questionnaire

FOLFOX regimen

CAPOX regimen

Docetaxel

5F U

Sponsor

NRG Oncology

Source: clinicaltrials.gov

Share:
Add to list

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Study ID: NCT04049331
Start Date: 2021-03-22
End Date: 2027-01-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

240

Intervention / Treatment

Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]

placebo

Sponsor

Seattle Institute for Biomedical and Clinical Research

Source: clinicaltrials.gov

Share:
Add to list

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Study ID: NCT05010031
Start Date: 2021-08-11
End Date: 2026-08
Study Type

Interventional

Study Phase

Phase2

No. of Participants

29

Intervention / Treatment

Palliative radiotherapy

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Study ID: NCT05360160
Start Date: 2022-10-14
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

43

Intervention / Treatment

SNDX-5613

Venetoclax

ASTX727

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Study ID: NCT05034627
Start Date: 2022-08-09
End Date: 2026-10-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

15

Intervention / Treatment

Biopsy

CALASPARGASE PEGOL-MKNL

Cobiet

Sponsor

OHSU Knight Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Study ID: NCT05773274
Start Date: 2024-01-12
End Date: 2026-04-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Everolimus

Lutetium Lu 177 dotatate

Quality-of-Life Assessment

Administration questionnaire

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Optical Sensor for Photodynamic Detection of Oral Pathology

Study ID: NCT00540774
Start Date: 2003-04
End Date: 2028-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

2500

Intervention / Treatment

detection of oral pathology

Sponsor

University of California, Irvine

Source: clinicaltrials.gov

Share:
Add to list

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Study ID: NCT05485974
Start Date: 2022-08-01
End Date: 2025-08
Study Type

Interventional

Study Phase

Phase1

No. of Participants

44

Intervention / Treatment

HBI-2438

Sponsor

HUYABIO International, LLC.

Source: clinicaltrials.gov

Share:
Add to list

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Study ID: NCT06107374
Start Date: 2023-11-01
End Date: 2026-03-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

[18pm] f-arg

Sponsor

CellSight Technologies, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Study ID: NCT05963074
Start Date: 2024-05-30
End Date: 2029-03-19
Study Type

Interventional

Study Phase

Phase2

No. of Participants

320

Intervention / Treatment

Ibrutinib

Venetoclax

Sponsor

Janssen Research & Development, LLC

Source: clinicaltrials.gov

Share:
Add to list